Treatment Information

Back

Melanoma treatment details. Chemotherapy, Immunotherapy.

Campus Benjamin Franklin, Berlin, Germany.

Survival: monthsCountry:Germany
Toxiciy Grade:4City/State/Province:Berlin
Treatments:Chemotherapy, ImmunotherapyHospital:Campus Benjamin Franklin
Drugs:Journal:Link
Date:Sep 2005

Description:

Patients: This Phase III study involved a total of 363 patients with metastatic melanoma who were divided into two groups: Group A of 180 patients and Group B of 183 patients. For Group B the median age was 48.

Treatment: The treatment for Group B consisted of two chemotherapy agents (Dacarbazine and Cisplatin) and two immunotherapy agents (interferon-alpha-2b and interleukin-2).

Toxicity: Grade 4 toxicities for this group included: dyrhythmias, cardiovascular dysfunction, hyper or hypotension, various gastrointestinal toxicities, neuropathy, and pulmonary. There were also grade 3-4 hematologic toxicities.

Results: The median overall survival was 9 months.

Support: Several of the authors had received consulting, honorarian or research funding from Schering Plough. This company markets interferon-alpha-2b.

Correspondence: Ulrich Keilholz, MD




Back